HALOHealthcare · BiotechnologyThe 9 Wall Street analysts covering Halozyme Therapeutics, Inc. hold a median 12-month price target of $110 — -14.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 26 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Halozyme Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Issuance (45): The company has been issuing shares or taking on financing, diluting existing holders.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on HALO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −14.4% from it.
Of the 20 most recent actions, 8 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $105 → $130 |
| 8 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $115 → $130 |
| 8 Oct 2026 | JP Morgan | Maintains | Neutral | $70 → $78 |
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $115 |
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Aug 2026 | Leerink Partners | Upgrade | Outperform | — |
| 7 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 7 Aug 2026 | Citizens | Maintains | Market Outperform | $92 → $93 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $95 → $115 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Aug 2026 | Leerink Partners | Upgrade | Outperform | $83 → $110 |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | $96 → $105 |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $75 → $95 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $95 |
| 12 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 12 May 2026 | Morgan Stanley | Maintains | Overweight | $96 → $93 |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HALO appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Halozyme Therapeutics, Inc. returned +95.1% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 15% of US stocks
Cheaper than 2% of US stocks
Cheaper than 22% of US stocks
Higher than 85% of US stocks
Higher than 71% of US stocks
Higher than 93% of US stocks
Higher than 98% of US stocks
Higher than 86% of US stocks
Higher than 98% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Halozyme Therapeutics, Inc. has a market value of $14.3B and an enterprise value of $16.2B.
Revenue in the twelve months to 30 June 2026: $1.7B. The latest quarter grew 47.7% year on year.
Net income over the same four quarters: $413.6M, a 24.9% net margin.
Diluted earnings per share, trailing twelve months: $3.35.
Free cash flow in the twelve months to 30 June 2026: $518.5M.
Trailing P/E: 36.7×; forward P/E: 11.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Halozyme Therapeutics, Inc. employs 423 people — $3.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Halozyme Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The article highlights Halozyme’s drug-delivery technologies, which can enable medicines normally administered by IV infusion to be given as under-the-skin injections. Its headline says the company is up 80% this year, rivaling Merck and reaching new highs.
Why it matters — HALO watchers may note the article’s focus on its drug-delivery technology and recent performance.
Halozyme announced it will report third-quarter 2026 financial and operating results after the market closes on November 5, 2026. The company will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the results.
Why it matters — HALO watchers can note the scheduled date and time for the company’s quarterly results and discussion.
Zacks Investment Research highlighted five Strong Buy stocks ahead of earnings, citing high operating margins, revenue growth, and exposure to AI, healthcare, energy, and digital payments.
Why it matters — The item mentions healthcare among the featured sectors but does not identify Halozyme or provide company-specific information.
FXEmpire reports that Halozyme Therapeutics shares have risen 910% since March 2014, in a headline describing strong earnings growth.
Why it matters — The report highlights a substantial long-term share gain and connects it with Halozyme's earnings growth.
Zacks Investment Research named HALO among five stocks standing out as relative-strength picks amid market volatility, citing strong price performance and upbeat earnings estimates.
Why it matters — The item highlights HALO’s price performance and earnings estimates as factors in its inclusion among the relative-strength picks.
The 9 Wall Street analysts covering Halozyme Therapeutics, Inc. have a median 12-month price target of $110, with estimates ranging from $78 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Halozyme Therapeutics, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Halozyme Therapeutics, Inc. 98 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, Halozyme Therapeutics, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies -14.4% from the last close, and Ticker Nerd's factor model ranks Halozyme Therapeutics, Inc. 98 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Halozyme Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HALO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $78 to $130 over the next 12 months.
Halozyme Therapeutics, Inc. returned +95.1% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines.
The most recent item we track (Investors Business Daily, 23 Oct 2026): "How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs". The article highlights Halozyme’s drug-delivery technologies, which can enable medicines normally administered by IV infusion to be given as under-the-skin injections. Its headline says the company is up 80% this year, rivaling Merck and reaching new highs.
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.
CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. · 423 employees · United States · https://halozyme.com
